401 related articles for article (PubMed ID: 10089889)
1. Current controversies in breast cancer management.
Morrow M; Jordan VC; Takei H; Gradishar WJ; Pierce LJ
Curr Probl Surg; 1999 Mar; 36(3):163-216. PubMed ID: 10089889
[No Abstract] [Full Text] [Related]
2. Breast cancer highlights.
Kuter I
Oncologist; 1999; 4(4):299-308. PubMed ID: 10476541
[No Abstract] [Full Text] [Related]
3. Estrogen receptor as a target for the prevention of breast cancer.
Jordan VC
J Lab Clin Med; 1999 May; 133(5):408-14. PubMed ID: 10235123
[No Abstract] [Full Text] [Related]
4. [Adjuvant therapy in breast cancer].
Semiglazov VF
Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
[No Abstract] [Full Text] [Related]
5. Overview of randomized trials of systemic adjuvant therapy.
Ravdin PM
Cancer Treat Res; 2000; 103():157-81. PubMed ID: 10948446
[No Abstract] [Full Text] [Related]
6. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Pritchard KI
Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
[No Abstract] [Full Text] [Related]
7. Radiotherapy and tamoxifen after breast-conserving surgery for DCIS.
Cunnick GH; Mokbel K
Int J Fertil Womens Med; 2004; 49(5):237-8. PubMed ID: 15633483
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen versus raloxifene in the prevention of breast cancer.
Wickerham DL
Eur J Cancer; 2002 Nov; 38 Suppl 6():S20-1. PubMed ID: 12409060
[No Abstract] [Full Text] [Related]
9. [Tamoxifen and breast cancer: is everything known already?].
Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
[No Abstract] [Full Text] [Related]
10. In search of the perfect SERM: beyond tamoxifen and raloxifene.
McNeil C
J Natl Cancer Inst; 1998 Jul; 90(13):956-7. PubMed ID: 9665139
[No Abstract] [Full Text] [Related]
11. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen debate hinges on whose risk is high enough.
Reynolds T
J Natl Cancer Inst; 1998 Oct; 90(19):1428-30. PubMed ID: 9776407
[No Abstract] [Full Text] [Related]
13. The duration of adjuvant tamoxifen therapy.
Bilimoria MM; Jordan VC
Cancer Treat Res; 1998; 94():181-93. PubMed ID: 9587688
[No Abstract] [Full Text] [Related]
14. NCCN Guideline update: Breast Cancer Version 1.2004.
National Comprehensive Cancer Network
J Natl Compr Canc Netw; 2004 May; 2(3):183-4. PubMed ID: 19795602
[No Abstract] [Full Text] [Related]
15. Status of antiestrogen breast cancer prevention trials.
Powles TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
[TBL] [Abstract][Full Text] [Related]
16. STAR trial reports.
Eur J Cancer; 2006 Aug; 42(12):1694. PubMed ID: 16998956
[No Abstract] [Full Text] [Related]
17. Current status of tamoxifen use: An update for the surgical oncologist.
Heerdt AS; Borgen PI
J Surg Oncol; 1999 Sep; 72(1):42-9. PubMed ID: 10477879
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
19. Anti-estrogens come of age: a pioneer looks back.
Nelson NJ
J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
[No Abstract] [Full Text] [Related]
20. Adjuvant systemic therapy for early breast cancer: progress and controversies.
Hortobagyi GN
Clin Cancer Res; 2001 Jul; 7(7):1839-42. PubMed ID: 11448893
[No Abstract] [Full Text] [Related]
[Next] [New Search]
